A New Methodology for the Prevention of Respiratory Complications
Key inventor
Dr David Tingay, Phd MBBS
Summary of the opportunity
We have developed a new algorithm for ventilators to reduce the
risk of respiratory complication. The new algorithm is based on an
existing parameter currently measured by the majority of mechanical
ventilators and therefore can easily be included in existing
machines and provide a partnering ventilator company with a
competitive edge in the neonatal and critical setting.
The Problem / Target Market
Mechanical ventilation is life saving and safe, nonetheless, when
applied poorly the lung is at risk of injury from either inadequate
or excessive applied pressure; both PIP and PEEP.
Nearly all modern ventilators have in built modes that try to
avoid the inadvertent delivery of excessive PIP based on a
volume-targeted algorithm. However; there is now evidence in all
age groups that inappropriate PEEP results in greater lung injury
and mortality.
The world market for mechanical ventilators is estimated to be
approximately $2 billion in 2010 (Marketstrat®).The market drivers
are the aging population and increasing rates of COPD and emerging
medical markets in the developing world. The number of prevalent
cases of COPD in China is anticipated to increase substantially
between 2010 and 2020, increasing from approximately 42 million to
nearly 56 million (Datamonitor)
The major market targeted for this technology is the Neonatal and
Critical Care setting. However; we anticipate that with the
increasing home care market segment the technology will be
adaptable to ventilators with non leaking face masks to take
advantage of this fast growing segment.
Market leaders and potential partners in this sector are Draeger,
Covidien and CareFusion, GE healthcare (VersaMed, Breas), Philips,
Maquet and Hamilton Medical.
Technology, Stage of Development and Competitive
Edge
The patented Technology has been demonstrated in animal
models.
It has various advantageous over existing technology currently
being used in ventilator systems.
- The Technology is individualised to each patient
- The Technology is based solely on a parameter only influenced
by the lung.
- The Technology is independent of oxygenation.
- There is a minimisation of adverse events and a reduction in
the risk of inadvertently high PIP being applied during the
procedure.
- It uses a parameter already measured by modern ventilators and
used in other ventilator algorithms which will facilitate easy
integration into current ventilator software algorithms with the
clinician only required to adjust one
Nature of the Deal
The Murdoch Childrens Research Institute has patented the
technology and is seeking to develop a partnership with industry
with the aim to secure a licensing partner to further develop this
technology to its full potential.